Longitudinal tracking of Ag85A-specific IFN-γ ELISPOT responses in subjects vaccinated with MVA85A 3 to 6 years ago.

<p>Red data points denote measurements from individuals who became infected with <i>M.tb</i> since completion of the original clinical trial. <i>M.tb</i> infection was defined as conversion to a positive IFN-γ ELISpot assay response to ESAT-6/CFP-10. Frequencies of IFN-γ spot forming cells (SFC) detected before vaccination and at the last time point after MVA85A vaccination were compared using the Wilcoxon signed rank test. Blue p-values denote comparison of data from all individuals, while red p-values denote comparison of <i>M.tb</i>-uninfected (negative responders to ESAT-6/CFP-10) individuals only. (<b>A–D</b>) Longitudinal tracking of Ag85A-specific T cell responses in adults (<b>A</b>, n = 17), adolescents (<b>B</b>, n = 9), children (<b>C</b>, n = 15) and infants (<b>D</b>, n = 27), who received 5×10⁷ plaque forming units (pfu) of MVA85A. (<b>E</b>) Comparison of Ag85A-specific IFN-γ ELISPOT responses in subjects who were vaccinated more than 3 years ago with different doses of MVA85A as infants, or who received the placebo vaccine, Prevenar (n = 24 for Group 1, n = 27 for Group 2; n = 24 for Group 3 and n = 23 for the placebo Group). The overall effect was calculated using the Kruskal-Wallis test, while responses in each dose group were compared to the placebo group using the Mann-Whitney U test. Median and IQR IFN-γ ELISPOT response values are shown in <b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0087340#pone.0087340.s004" target="_blank">Table S1</a></b>.